Investment analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ - Get Free Report) in a report issued on Sunday. The brokerage set a "hold" rating on the medical research company's stock.
Enzo Biochem Stock Up 4.9 %
Enzo Biochem stock traded up $0.05 during mid-day trading on Friday, hitting $1.08. The company's stock had a trading volume of 203,024 shares, compared to its average volume of 141,941. Enzo Biochem has a 52-week low of $0.93 and a 52-week high of $1.50. The firm's 50 day moving average is $1.11 and its 200 day moving average is $1.11.
Hedge Funds Weigh In On Enzo Biochem
Several hedge funds and other institutional investors have recently modified their holdings of ENZ. Geode Capital Management LLC boosted its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company's stock valued at $413,000 after purchasing an additional 11,742 shares during the last quarter. BBR Partners LLC acquired a new position in shares of Enzo Biochem in the 3rd quarter valued at approximately $112,000. XTX Topco Ltd increased its holdings in Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company's stock worth $31,000 after purchasing an additional 13,735 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company's stock worth $2,725,000 after acquiring an additional 64,417 shares in the last quarter. Institutional investors own 36.90% of the company's stock.
About Enzo Biochem
(
Get Free Report)
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Stories
Before you consider Enzo Biochem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzo Biochem wasn't on the list.
While Enzo Biochem currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
